View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 8, 2019updated 10 Jan 2019 12:12pm

Takeda completes $62bn Shire acquisition

Japan-based Takeda Pharmaceutical has officially completed the acquisition of UK headquartered Shire for a total consideration of $62bn. This makes Takeda one of the top ten pharmaceutical companies in the world.

Japan-based Takeda Pharmaceutical has officially completed the acquisition of UK headquartered Shire for a total consideration of $62bn. This makes Takeda one of the top ten pharmaceutical companies in the world.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Shire agreed to the takeover in May last year, after receiving a series of bids from the Japanese pharmaceutical company. The deal was subject to multiple customary approvals.

While the Japan Fair Trade Commission approved the deal in October last year, the UK court sanctioned it on 3 January this year. Takeda shareholders approved the deal  last month.

Takeda said that the acquisition provides an expanded geographic footprint and position in Japan as well as the US. The company will be able to cater to around 80 countries or regions.

The company’s research and development (R&D) is focussed on oncology, gastroenterology (GI), neuroscience and rare diseases, along with plasma-derived therapies (PDT) and vaccines.

Takeda added that the combined annual revenue of the company is set to be more than $30bn, and will primarily come from the oncology, GI, neuroscience, rare diseases and PDT areas.

Takeda president and CEO Christophe Weber said: “This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicines to patients around the world with expanded scale and geographical footprint.

“We are confident in our ability to execute a smooth integration under the leadership of our experienced and diverse Takeda Executive Team.”

“The execution of our integration begins today, and we are confident in our ability to execute a smooth integration under the leadership of our experienced and diverse Takeda Executive Team with a strong track record.”

The Japanese company is reportedly planning to sell non-core assets worth up to $10bn to mitigate the debt load associated with this biggest announced acquisition of last year.

However, the deal has been already superseded by Bristol-Myers Squibb’s recent $74bn proposal to acquire Celgene.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology